IECM
ATRS

Intrinsic Edge Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Intrinsic Edge Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-641,512
Closed -$1.76M – 305
2020
Q2 		$1.76M Sell
641,512
-358,488
-36% -$1M 0.16% 172
2020
Q1 		$2.36M Buy
+1,000,000
New +$3.4M 0.31% 98

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Intrinsic Edge Capital Management's ATRS Position: Q3 2020 in Review

Intrinsic Edge Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2020, closing a stake of 641,512 shares — an estimated $1.76M sold.

Intrinsic Edge Capital Management first reported a position in ATRS in Q1 2020 and held it in 2 quarters. The position peaked at $2.36M in Q1 2020. 164 funds tracked by Wall St. Rank hold ATRS as of Q3 2020.

  • Intrinsic Edge Capital Management reported no remaining Antares Pharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 641,512 Antares Pharma, Inc. shares in Q3 2020, an estimated $1.76M.
  • Intrinsic Edge Capital Management first reported a position in Antares Pharma, Inc. in Q1 2020 and held it in 2 quarters.
  • Intrinsic Edge Capital Management's Antares Pharma, Inc. position peaked at $2.36M in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2020.

Based on Intrinsic Edge Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.